X4 Pharmaceuticals, Inc. XFOR

- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial. The pu

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway into 2029 - BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today repor

Kelly Gold Kelly Gold has been appointed to the X4 Pharmaceuticals Board of Directors. BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee. “We are thrilled

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmaceuticals is a company focu

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are tying this change closely to expectations around mavorixafor in WHIM syndrome and primary chronic neutropenia, and to how much of that story is already reflected in the stock. As you read on, you will see how different analysts are framing this shift and what to watch as the narrative...

With a stock price of $4.41, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is among the 10 Unrivaled Penny Stocks to Buy Now. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst consensus estimates of $3.2 million. Management stated that its top priority remains the execution and enrollment of the pivotal Phase 3 […]